Ian Peikonm, PhD

Ian Peikon, PhD, is a molecular biologist and neuroscientist. He is the co-founder and co-CEO of Cajal Therapeutics, where he leads a team developing new medicines for diseases with high unmet need, including Parkinson’s disease. Previously, Ian co-founded Kallyope, where he served as Director of Platform Biology & Technology, and VNV Bio, a non-viral gene therapy company acquired by Aera Therapeutics.His scientific work ranges from early work in brain-machine interfaces and, more recently, therapeutic development across multiple disease areas. He earned his PhD from Cold Spring Harbor Laboratory. In addition to his operating role at Cajal, Ian currently serves on the board of Plexium Inc. and is a Venture Partner at Lux Capital.